Peptichemio

A mixture of six synthetic oligopeptides, each containing MELPHALAN. It is used as a broad-spectrum antineoplastic due to its alkylating and antimetabolic actions but, is toxic to bone marrow, gastrointestinal system and vasculature.

Networked: 59 relevant articles (4 outcomes, 6 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Dhar, Sumeer: 1 article (09/2003)
2.	Ehrsson, Hans: 1 article (09/2003)
3.	Gullbo, Joachim: 1 article (09/2003)
4.	Larsson, Rolf: 1 article (09/2003)
5.	Lewensohn, Rolf: 1 article (09/2003)
6.	Luthman, Kristina: 1 article (09/2003)
7.	Nygren, Peter: 1 article (09/2003)

Related Diseases

1.	Neuroblastoma 07/01/1989 - "The aim of this study was to evaluate the antitumor effect and toxicity of a single course of Peptichemio at high dose (450 mg/sq m) given to children with neuroblastoma resistant to first line treatment or at relapse. " 05/15/1978 - "[Efficacy of peptichemio in neuroblastoma]." 07/01/1989 - "High dose peptichemio in pretreated neuroblastoma." 01/01/1984 - "Peptichemio in neuroblastoma at relapse." 07/01/1982 - "Effect of peptichemio in nonlocalized neuroblastoma."
2.	Lymphoma (Lymphomas) 08/01/1977 - "Lethal and kinetic effects of peptichemio on cultured human lymphoma cells." 04/01/1974 - "[Treatment of malignant lymphoma with Peptichemio. " 06/13/1975 - "[Treatment of malignant lymphomas with shock doses of peptichemio]." 03/01/1977 - "Peptichemio: A new oncolytic drug in combination with vincristine and prednisolone in the treatment of non-Hodgkin lymphomas." 03/01/1977 - "Peptichemio, a new oncolytic drug with alkylating and antimetabolic properties was employed in combination with vincristine and 6-methylprednisolone (PVP) for the treatment of diffuse non-Hodgkin's lymphomas (NHL), stages III and IV. 52 of 66 patients who entered the PVP protocol were considered evaluable: the overall remission rate in diffuse lymphocytic poorly differentiated lymphomas (DLPD) was 56.6 and 55% in diffuse histiocytic lymphomas (DHL). "
3.	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 03/01/1977 - "Peptichemio, a new oncolytic drug with alkylating and antimetabolic properties was employed in combination with vincristine and 6-methylprednisolone (PVP) for the treatment of diffuse non-Hodgkin's lymphomas (NHL), stages III and IV. 52 of 66 patients who entered the PVP protocol were considered evaluable: the overall remission rate in diffuse lymphocytic poorly differentiated lymphomas (DLPD) was 56.6 and 55% in diffuse histiocytic lymphomas (DHL). "
4.	Plasma Cell Leukemia 01/01/1982 - "Peptichemio was shown to be effective in patients in an advanced stage of the disease, in patients with light-chain myeloma and in those with plasma cell leukemia. "
5.	Breast Neoplasms (Breast Cancer) 05/15/1980 - "A phase II study of peptichemio in advanced breast cancer." 05/01/1986 - "A clinical evaluation of peptichemio (40-45 mg/m2/day for 3 days every 3-4 weeks) was conducted in 32 patients with advanced breast cancer, 28 of whom were evaluable for both toxicity and response. " 05/01/1986 - "Peptichemio in advanced breast cancer: a clinical evaluation in 32 patients." 05/01/1984 - "Although peptichemio used as a single agent had significant activity against breast cancer, it was not suitable for prolonged use in conjunction with other myelosuppressive agents. " 01/01/1974 - "[Use of Peptichemio in the treatment of breast carcinoma in the advanced phase]."

Related Drugs and Biologics

1.	Vincristine (Oncovin)
2.	Methylprednisolone
3.	Cyclophosphamide (Cytoxan)
4.	Cisplatin (Platino)
5.	Amsacrine (AMSA)
6.	Melphalan (Alkeran)
7.	Prednisone (Sone)
8.	Fluorouracil (Carac)
9.	Doxorubicin (Adriamycin)
10.	Peptides (Polypeptides)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Combination Drug Therapy (Combination Chemotherapy)
4.	Radiotherapy
5.	Aftercare (After-Treatment)